Melane Sampson, Author at BioTuesdays

Developments

Rallybio launches Phase II trial of RLYB212 for FNAIT in pregnancy

Rallybio (NASDAQ:RLYB) announced the commencement of an open-label Phase II trial of RLYB212 in pregnant women at high-risk of HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). FNAIT is...

November 22, 2024

Executive Moves

MOBILion launches proteomics advisory board

Closely-held MOBILion Systems announced the formation of a proteomics advisory board to provide strategic guidance as the company advances the development of its next-generation high-resolution mass spectrometry...

November 20, 2024

Developments

Neurizon reports positive results from preclinical study of NUZ-001 in ALS

Neurizon Therapeutics (ASX: NUZ & NUZOA) announced positive results from a preclinical study of its lead candidate, NUZ-001, in amyotrophic lateral sclerosis (ALS). The company states that NUZ-001 reduces the...

November 19, 2024

Developments

Adverum announces positive 52-week LUNA results and four-year OPTIC data

Adverum Biotechnologies (NASDAQ:ADVM) announced topline 52-week results from its LUNA Phase 2 trial, new four-year long-term follow-up data from its OPTIC study, and key design elements for its pivotal program. Both the...

November 18, 2024

Developments

Therma Bright to spin off consumer product portfolio creating new company

Therma Bright (TSXV:THRM; QTCQB:TBRIF) announced plans to spin off its consumer product portfolio into a separate publicly traded company during the first half of 2025. The spin-off transaction will be subject to...

November 18, 2024

Executive Moves

MindMed names Gregg Pratt as chief regulatory and quality assurance officer

MindMed (NASDAQ:MNMD) has appointed Gregg Pratt, Ph.D., as chief regulatory and quality assurance officer. Dr. Pratt will oversee the company’s regulatory and quality functions, as well as its product registration...

November 18, 2024

Developments

AC Immune announces positive interim results from study of ACI-7104.056 in Parkinson’s

AC Immune (NASDAQ:ACIU) announced positive interim safety and immunogenicity data from its Phase 2 VacSYn clinical trial, evaluating ACI-7104.056 as a treatment for patients with early Parkinson’s disease. The company...

November 15, 2024

Developments

Moleculin amends protocol for Phase 3 trial of Annamycin for AML

Moleculin Biotech (NASDAQ:MBRX) announced it has amended the protocol with the FDA for its Phase 3 pivotal MIRACLE trial, evaluating Annamycin in combination with Cytarabine for treating patients with acute myeloid...

November 14, 2024

Feature

Spectral combining diagnostics with targeted therapy in novel approach to septic shock

Spectral Medical (TSX: EDT) is seeking to improve outcomes for millions of patients with life-threatening endotoxic septic shock (ESS), by combining its targeted diagnostic, Endotoxin Activity Assay (EAA), with its...

November 12, 2024

Developments

FDA grants ODD to Mustang’s MB-108 for malignant glioma

Mustang Bio (NASDAQ:MBIO) announced that the FDA has granted orphan drug designation (ODD) to MB-108, an HSV-1 oncolytic virus and a component of MB-109, for the treatment of malignant glioma. MB-109 combines MB-101, a...

November 8, 2024

Author - Melane Sampson

Rallybio launches Phase II trial of RLYB212 for FNAIT in pregnancy

MOBILion launches proteomics advisory board

Neurizon reports positive results from preclinical study of NUZ-001 in ALS

Adverum announces positive 52-week LUNA results and four-year OPTIC data

Therma Bright to spin off consumer product portfolio creating new company

MindMed names Gregg Pratt as chief regulatory and quality assurance officer

AC Immune announces positive interim results from study of ACI-7104.056 in Parkinson’s

Moleculin amends protocol for Phase 3 trial of Annamycin for AML

Spectral combining diagnostics with targeted therapy in novel approach to septic shock

FDA grants ODD to Mustang’s MB-108 for malignant glioma

General

More